<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05089708</url>
  </required_header>
  <id_info>
    <org_study_id>RD.06.SPR.204245</org_study_id>
    <nct_id>NCT05089708</nct_id>
  </id_info>
  <brief_title>AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation</brief_title>
  <acronym>LEAP</acronym>
  <official_title>Evaluation of Acne-induced Hyperpigmentation During Treatment of Acne Vulgaris Subjects With Trifarotene 50 Î¼g/g Cream Versus Vehicle Cream Over 24 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma R&amp;D</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Trifarotene 50 microgram&#xD;
      per gram (mcg/g) cream compared to its vehicle cream in the treatment of moderate acne&#xD;
      vulagris with risk of acne-induced post inflammatory hyperpigmentation (PIH) after 24 weeks&#xD;
      of treatment in facial acne participants&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 31, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change From Baseline in Post-Inflammatory Hyperpigmentation (PIH) Overall Disease Severity Scores at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>PIH improvement assessment was based on a 7-point Likert scale ranging from -3 (much darker) to 3 (much lighter), higher score = improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in PIH Overall Disease Severity Scores at Week 24</measure>
    <time_frame>Baseline upto Week 24</time_frame>
    <description>PIH improvement assessment was based on a 7-point Likert scale ranging from -3 (much darker) to 3 (much lighter), higher score = improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in PIH Overall Disease Severity Scores at Week 12, 16 and 20</measure>
    <time_frame>Baseline, Week 12, Week 16 and Week 20</time_frame>
    <description>PIH improvement assessment was based on a 7-point Likert scale ranging from -3 (much darker) to 3 (much lighter), higher score = improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in PIH Overall Disease Severity Scores at Week 12, 16 and 20</measure>
    <time_frame>Baseline, Week 12, Week 16 and Week 20</time_frame>
    <description>PIH improvement assessment was based on a 7-point Likert scale ranging from -3 (much darker) to 3 (much lighter), higher score = improvement.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Trifarotene (CD5789) 50 mcg/g Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Trifarotene Vehicle Cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trifarotene Cream</intervention_name>
    <description>Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream on the face once daily, in the evening for 24 weeks</description>
    <arm_group_label>Trifarotene (CD5789) 50 mcg/g Cream</arm_group_label>
    <other_name>Aklief</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trifarotene Vehicle Cream</intervention_name>
    <description>Participants will apply a thin a layer of trifarotene vehicle cream on the face once daily, in the evening for 24 weeks</description>
    <arm_group_label>Trifarotene Vehicle Cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Participant with clinical diagnosis of acne vulgaris, defined by:&#xD;
&#xD;
               1. moderate acne on the face (acne Investigator's Global Assessment [IGA] =3); and&#xD;
&#xD;
               2. with minimum of 20 inflammatory lesions and 25 non inflammatory lesions on the&#xD;
                  face (excluding the nose); and&#xD;
&#xD;
               3. moderate to marked PIH on the face (Overview of Pigmentation Disorders [ODS]&#xD;
                  hyperpigmentation scale 4-6); and&#xD;
&#xD;
               4. no more than one acne nodule or cyst (greater than [&gt;] 1 centimeter [cm]) on face&#xD;
                  (excluding the nose)&#xD;
&#xD;
          -  Participant with any Fitzpatrick Skin Type I to VI (target patient enrollment&#xD;
             according to FST)&#xD;
&#xD;
          -  Female participants of childbearing potential must have a negative urine pregnancy&#xD;
             test (UPT) at Baseline visit&#xD;
&#xD;
          -  Female participants of childbearing potential must agree to use an adequate and&#xD;
             approved method of contraception throughout the study&#xD;
&#xD;
          -  Female participant of non-childbearing potential&#xD;
&#xD;
          -  Other protocol defined inclusion criteria could apply&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Participant with severe acne (IGA &gt; 3)&#xD;
&#xD;
          -  Participant with more than 1 nodule/cyst on the face (excluding the nose)&#xD;
&#xD;
          -  Participant with acne conglobata, acne fulminans, secondary acne, nodulocystic acne,&#xD;
             acne requiring systemic treatment&#xD;
&#xD;
          -  Participant with damaged facial skin that may interfere with study assessments&#xD;
&#xD;
          -  Female participant who is pregnant, lactating or planning a pregnancy during the study&#xD;
&#xD;
          -  Female participant of childbearing potential using combined oral contraceptives&#xD;
             approved as acne treatments, in whom the dose has not been stable for at least 6&#xD;
             months prior to the Baseline visit&#xD;
&#xD;
          -  Participant with known impaired hepatic or renal functions&#xD;
&#xD;
          -  Participant with active or chronic skin allergies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Galderma Research &amp; Development</last_name>
    <phone>(817) 961-5000</phone>
    <email>clinical.studies@galderma.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 11, 2021</study_first_submitted>
  <study_first_submitted_qc>October 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acne vulgaris</keyword>
  <keyword>Trifarotene</keyword>
  <keyword>Aklief</keyword>
  <keyword>CD5789</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
    <mesh_term>Hyperpigmentation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trifarotene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

